Cofounder in Residence, Next Generation Therapeutics for Parkinsons Disease

Work set-up: 
Full Remote
Contract: 
Salary: 
5 - 5K yearly
Experience: 
Mid-level (2-5 years)
Work from: 

Offer summary

Qualifications:

PhD in neuroscience or a related field., Extensive knowledge of Parkinson’s disease at cellular and molecular levels., Experience in cellular, molecular, or biochemical drug discovery approaches for CNS disorders., Strong commercial awareness and entrepreneurial spirit, with experience in biotech or pharma settings..

Key responsibilities:

  • Participate in venture creation to develop a new company focused on Parkinson’s therapeutics.
  • Work on designing and building the business case for the new venture.
  • Collaborate with the DSV team using their methodology to identify optimal solutions.
  • Contribute to all aspects of venture development, from team building to securing investment.

Deep Science Ventures logo
Deep Science Ventures Startup deepscienceventures.com
11 - 50 Employees
See all jobs

Job description

ABOUT THE ROLE

At DSV we’re looking for future Founders, entrepreneurially minded individuals with industryspecific technical and commercial domain expertise eager to solve urgent unmet challenges through venture building.

You will join DSV’s venture creation programme as a Founder in Residence and work closely with the DSV team, using our methodology, to spinout a new company. During the programme, you’ll work on all aspects related to venture creation in this opportunity area, including working out the optimal approach to solve for the desired outcome, building a team and building a viable business case. Once the new venture is incorporated with preseed investment from DSV, you and your cofounders will own the majority stake in the business and continue receiving support from the DSV team postspinout.

The role is fulltime, fully remote until venture incorporation and spinout, after TBD.

THE OPPORTUNITY AREA

Over 6 million individuals live with Parkinson’s disease (PD) today, and this number is projected to reach 12 million globally by 2040 as populations age. Whilst current therapies do offer symptomatic relief from debilitating motor symptoms, no clinically approved drug intervenes at root cause, meaning disease progression cannot be prevented. In addition, emerging therapeutics which show great promise in animal models of PD often fail to translate in the clinical setting, with even the most successful clinical trials reporting incremental benefit, often capped by dose limiting toxicity.

To address this, we are partnering with Parkinson’s UK to develop precise, next generation therapies which target true disease modifying nodes in previously unimagined ways. As PD is a multipathway pathology, spanning oxidative stress, impaired autophagy, mitochondrial dysfunction and neuroinflammation, the efficacy of single pathway approaches is constrained.

OUR APPROACH

We are designing a therapeutic approach that will target master homeostatic regulators which can simultaneously correct numerous PD pathways, changing the course of disease. We believe this has the potential to transform patient lives by slowing, halting or even reversing disease progression. This pathway has been the focus of drug development in the past but not been drugged successfully through classic approaches. We are looking to unlock this through the use of novel modalities and a clever target selection and targeting strategy that has the potential to overcome the many feedback looks regulating this pathway.

Requirements

WHO SHOULD APPLY

Essential (musthave):

Required profile

Experience

Level of experience: Mid-level (2-5 years)
Spoken language(s):
English
Check out the description to know which languages are mandatory.

Other Skills

  • Creative Thinking
  • Innovation
  • Self-Motivation

Related jobs